Thomas E. Hutson, DO, PharmD | Authors

Articles

An Analysis of the Phase III ATLAS Trial in RCC​

August 06, 2014

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).

BPX-201 Vaccine for Chemotherapy-Naïve mCRPC

June 10, 2014

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses a phase I study of BPX-201 vaccine plus AP1903 for chemotherapy-naïve mCRPC.